AOA Dx Announces MassNextGen $87,500 Non-Dilutive Funding from Massachusetts Life Science Center

AOA Dx is proud to announce that they were awarded $87,500 and access to coaching from an exclusive network of Executive Coaches through the Massachusetts Life Sciences Center’s 2021 MassNextGen Program.  The program is focused on women-led early stage life science companies and is sponsored by Takeda, King Street Properties, Sanofi, Johnson & Johnson Innovation.

CEO & co-founder, Oriana Papin-Zoghbi competed with a large number of applicants to be a part of the MassNextGen 2021 Program. They were selected by the Massachusetts Life Science Center’s Executive Committee and Investment Committee.

The Massachusetts Life Science Center is putting a strong emphasis on supporting female CEO’s and founders. As of today, women make up 50% of the global population yet receive less than 10% of all funding to solve medical problems that affect women.

“We are honored to have been awarded funding and coaching from the Massachusetts Life Science Center. We are very much looking forward to participating in the MassNextGen 2021 Program to help us further develop our business strategy, strengthen our technology and connect with some of the best minds in the life science space to help us reach our goals to provide a better future for women with ovarian cancer.” – Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx.

The Massachusetts Life Sciences Center’s mission is to serve as the hub of the world’s life sciences ecosystem, encourage innovation through investments in good science and business, strengthen and protect Massachusetts’ global leadership position in the life sciences, accelerate the commercialization of promising treatments, therapies, and cures that will improve patient care, create jobs, drive economic development and STEM workforce development. Since its creation in 2007, the MLSC has strategically deployed over $700 million in funding in Massachusetts.

About AOA Dx Inc.
AOA Dx Inc (AOA Inc) is a US company, with teams based in Boston, New York and London developing cancer diagnostics in the field of women’s health. AOA Dx Inc, a female led company, is committed to bringing the first accurate early stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers. More information can be found at

Corporate Communications